127 related articles for article (PubMed ID: 27009459)
1. Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis.
Hembree TN; Teer JK; Hakam A; Chiappori AA
Cancer Control; 2016 Jan; 23(1):61-6. PubMed ID: 27009459
[TBL] [Abstract][Full Text] [Related]
2. Molecular variations in uterine carcinosarcomas identify therapeutic opportunities.
Crane E; Naumann W; Tait D; Higgins R; Herzog T; Brown J
Int J Gynecol Cancer; 2020 Apr; 30(4):480-484. PubMed ID: 32114514
[TBL] [Abstract][Full Text] [Related]
3. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
[TBL] [Abstract][Full Text] [Related]
4. Integrated Molecular Characterization of Uterine Carcinosarcoma.
Cherniack AD; Shen H; Walter V; Stewart C; Murray BA; Bowlby R; Hu X; Ling S; Soslow RA; Broaddus RR; Zuna RE; Robertson G; Laird PW; Kucherlapati R; Mills GB; ; Weinstein JN; Zhang J; Akbani R; Levine DA
Cancer Cell; 2017 Mar; 31(3):411-423. PubMed ID: 28292439
[TBL] [Abstract][Full Text] [Related]
5. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
6. Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.
Chiba Y; Sato S; Itamochi H; Suga Y; Fukagawa T; Oumi N; Oishi T; Harada T; Sugai T; Sugiyama T
Hum Cell; 2017 Apr; 30(2):140-148. PubMed ID: 27889902
[TBL] [Abstract][Full Text] [Related]
7. RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma.
Mi S; Lin M; Brouwer-Visser J; Heim J; Smotkin D; Hebert T; Gunter MJ; Goldberg GL; Zheng D; Huang GS
Clin Cancer Res; 2016 Sep; 22(18):4676-86. PubMed ID: 27121792
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Bashir S; Jiang G; Joshi A; Miller C; Matrai C; Yemelyanova A; Caputo TA; Holcomb KM; Ellenson LH; Gupta D
Int J Gynecol Cancer; 2014 Sep; 24(7):1262-7. PubMed ID: 25078343
[TBL] [Abstract][Full Text] [Related]
9. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
10. Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma.
Inoue A; Yamaguchi K; Kurata Y; Murakami R; Abiko K; Hamanishi J; Kondoh E; Baba T; Kido A; Konishi I; Matsumura N
J Gynecol Oncol; 2017 Sep; 28(5):e62. PubMed ID: 28657223
[TBL] [Abstract][Full Text] [Related]
11. Tumor Mutational Burden Guides Therapy in a Treatment Refractory
Bhangoo MS; Boasberg P; Mehta P; Elvin JA; Ali SM; Wu W; Klempner SJ
Oncologist; 2018 May; 23(5):518-523. PubMed ID: 29386312
[TBL] [Abstract][Full Text] [Related]
12. FIGO staging for carcinosarcoma: can the revised staging system predict overall survival?
Pradhan TS; Stevens EE; Ablavsky M; Salame G; Lee YC; Abulafia O
Gynecol Oncol; 2011 Nov; 123(2):221-4. PubMed ID: 21889193
[TBL] [Abstract][Full Text] [Related]
13. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
[TBL] [Abstract][Full Text] [Related]
14. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
[TBL] [Abstract][Full Text] [Related]
15. [Uterine Carcinosarcoma: Clinicopathological Features and Prognostic Factors].
Luz R; Ferreira J; Rocha M; Jorge AF; Félix A
Acta Med Port; 2016 Oct; 29(10):621-628. PubMed ID: 28103458
[TBL] [Abstract][Full Text] [Related]
16. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma.
Clayton Smith D; Kenneth Macdonald O; Gaffney DK
Radiother Oncol; 2008 Aug; 88(2):227-32. PubMed ID: 18160157
[TBL] [Abstract][Full Text] [Related]
17. Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma.
Ashley CW; Da Cruz Paula A; Ferrando L; Gularte-Mérida R; Sebastiao APM; Brown DN; Gazzo AM; Pareja F; Stylianou A; Abu-Rustum NR; Reis-Filho JS; Buehler D; Weisman P; Chiang S; Weigelt B
Histopathology; 2021 Aug; 79(2):176-186. PubMed ID: 33527450
[TBL] [Abstract][Full Text] [Related]
18. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
Saglam O; Husain S; Toruner G
Int J Gynecol Pathol; 2013 Sep; 32(5):493-500. PubMed ID: 23896716
[TBL] [Abstract][Full Text] [Related]
19. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
Seagle BL; Kanis M; Kocherginsky M; Strauss JB; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):71-77. PubMed ID: 28317560
[TBL] [Abstract][Full Text] [Related]
20. Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma.
Fantappiè G; Malentacchi F; Turrini I; Sorbi F; Castiglione F; Vergoni F; Ammatuna C; Antonuzzo L; Fambrini M; Noci I; Pillozzi S
Anticancer Drugs; 2020 Sep; 31(8):880-883. PubMed ID: 32796408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
